In a significant development, AbbVie’s ADC has showcased its potential to revolutionize solid tumor treatment. Daiichi Sankyo and AstraZeneca are gearing up to unveil phase 3 clinical results for their highly anticipated ADC Enhertu at the upcoming American Society of Clinical Oncology conference. Having already received approval for multiple cancer indications, Enhertu made history as the first tumor-agnostic HER2-directed therapy sanctioned by the FDA last year. The forthcoming late-stage data could pave the way for extending Enhertu’s approval as a primary therapy for HER2-positive breast cancer, presenting a promising avenue for further growth in the field of oncology.
Read more about this — here
